{
    "clinical_study": {
        "@rank": "149480", 
        "arm_group": [
            {
                "arm_group_label": "Coenzyme Q10 concomitant treatment", 
                "arm_group_type": "Experimental", 
                "description": "Coenzyme Q10 concomitant treatment to fertility drugs as part of an IVF treatment\nDose: 600 mg by mouth daily beginning 3 months prior to IVF cycle. Patient will stop taking the CoEnzyme Q10 if conceives or when the study is completed.\nOther name: Ubiquinone"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "1 capsule by mouth daily beginning 3 months prior to IVF cycle. Patient will stop taking the placebo when she conceives or when the study is completed."
            }
        ], 
        "brief_summary": {
            "textblock": "The goal of the investigators research is to explore energy production of the ovarian\n      follicle in older reproductive age women at the time of oocyte retrieval."
        }, 
        "brief_title": "Co Enzyme Q10 Improves IVF Outcome in With Advanced Reproductive Age", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Ovarian Function at Advanced Reproductive Age", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 38-43 years at the time of enrollment\n\n          -  Diagnosis of primary infertility\n\n        Exclusion Criteria:\n\n          -  Body mass index (BMI) > 30 kg/m2\n\n          -  Early follicular phase (day 2-4) serum FSH level > 20 mIU/ml.\n\n          -  Abnormal uterine cavity as evidenced by sonohysterogram or hysterosalpingography\n\n          -  Any current use of systemic steroid medication or any infertility treatment within 3\n             months of study enrollment.\n\n          -  Any contraindication to being pregnant and carrying a pregnancy to term.\n\n          -  Contraindication for the use of CoQ10, or fertility medications.\n\n          -  Any ovarian or abdominal abnormality that may interfere with adequate TVS evaluation.\n\n          -  Absence of one or two ovaries\n\n          -  Clinically relevant systemic disease (e.g., Insulin-dependent diabetes, adrenal\n             dysfunction, organic intracranial lesion, polycystic ovarian syndrome,\n             hyperprolactinemia, or hypothalamic tumor) or serious illness (Neoplasia).\n\n          -  History (within past 12 months) or current abuse of alcohol or drugs.\n\n          -  Administration of any investigational drugs within three months prior to study\n             enrollment.\n\n          -  Any medical condition that may interfere with the absorption, distribution,\n             metabolism or excretion of the study drugs, gastrointestinal diseases, mal absorption\n             syndromes and liver dysfunction\n\n          -  Unexplained gynecological bleeding.\n\n          -  Ejaculated sperm is not sufficient for ICSI\n\n          -  Patient not able to communicate adequately with the investigators and to comply with\n             the requirements of the entire study.\n\n          -  Abnormal COH screening blood done for both partners, including: prolactin, thyroid\n             stimulating hormone, HIV serology, Hepatitis B and C serology, Rubella, group and\n             screen and syphilis serology prior to participation in study.\n\n          -  Unwillingness to give written informed consent. Previous entry into this study or\n             simultaneous participation in another clinical trial.\n\n          -  The concurrent use of any of the following drugs:\n\n          -  Daunorubicin, Doxorubicin, Blood Pressure Medications, Warfarin, Timolol,\n             atorvastatin, cerivastatin, lovastatin, pravastatin, simvastatin gemfibrozil,\n             tricyclic antidepressant medications (including amitriptyline, amoxapine,\n             clomipramine, desipramine, doxepin, imipramine, nortriptyline, protriptyline, and\n             trimipramine) multivitamins or any vitamin supplementation except Folic acid."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "43 Years", 
            "minimum_age": "38 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01659788", 
            "org_study_id": "CoEnzyme Q10-HMO-CTIL"
        }, 
        "intervention": [
            {
                "arm_group_label": "Coenzyme Q10 concomitant treatment", 
                "intervention_name": "Coenzyme Q10 concomitant treatment", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Coenzyme Q10", 
                "Ubiquinone"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Advanced Reproductive Age", 
            "poor ovarian response", 
            "Mitochondrial dysfunction", 
            "Mitochondrial nutrients", 
            "Coenzyme Q10", 
            "Electron transfer chain"
        ], 
        "lastchanged_date": "August 7, 2012", 
        "location": {
            "contact": {
                "email": "lhadas@hadassah.org.il", 
                "last_name": "Hadas Lamberg, PhD", 
                "phone": "00 972 2 677572"
            }, 
            "facility": {
                "address": {
                    "city": "Jerusalem", 
                    "country": "Israel"
                }, 
                "name": "Hadassah Medical Organization"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "2", 
        "official_title": "Co Enzyme Q10 Improves IVF Outcome in With Advanced Reproductive Age", 
        "other_outcome": {
            "measure": "Co Enzyme Q10 levels in maternal serum by HPLC", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "overall_contact": {
            "email": "kochman@hadassah.org.il", 
            "last_name": "Ronit Kochman, MD", 
            "phone": "00 972 50 8946414"
        }, 
        "overall_official": {
            "affiliation": "Hadassah Medical Organization", 
            "last_name": "Ronit Kochman, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Israel: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "level of ATP production", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Steriodogenesis associated enzymatic activity", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01659788"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Ovarian Response", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Embryo quality", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "cumulative pregnancy rate per retrieval", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "cumulative live birth rate per retrieval", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }
        ], 
        "source": "Hadassah Medical Organization", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hadassah Medical Organization", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}